IOLCP IOL Chemicals and Pharmaceuticals Q2 FY26 results (Jul–Sep 2025) and concall
IOL Chemicals delivered a solid Q2 FY26, with revenue growing 7.9% YoY to INR567.5 crores and EBITDA up 33.3% to INR64 crores, driven by volume recovery and cost efficiencies. PAT increased 56.7% to INR30 crores. The company experienced a temporary dip in sequential profitability due to elevated fuel costs, but expects normalization in Q3. Strategic focus remains on non-Ibuprofen APIs, paracetamol facility ramp-up, and diversification into regulated markets, with positive regulatory updates.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 8.0%, net profit up 57.9% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 526 | 523 | 528 | 552 | 568 +8% |
| EBITDA | 42 | 47 | 63 | 62 | 57 +36% |
| Net profit | 19 | 21 | 32 | 34 | 30 +58% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
